Antimetabolites, Antineoplastic
"Antimetabolites, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antimetabolites that are useful in cancer chemotherapy.
Descriptor ID |
D000964
|
MeSH Number(s) |
D27.505.519.186.144 D27.505.954.248.144 D27.888.569.042.030
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antimetabolites, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antimetabolites, Antineoplastic".
This graph shows the total number of publications written about "Antimetabolites, Antineoplastic" by people in this website by year, and whether "Antimetabolites, Antineoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 8 | 5 | 13 |
1996 | 10 | 6 | 16 |
1997 | 10 | 5 | 15 |
1998 | 13 | 7 | 20 |
1999 | 11 | 7 | 18 |
2000 | 7 | 5 | 12 |
2001 | 19 | 8 | 27 |
2002 | 13 | 12 | 25 |
2003 | 10 | 12 | 22 |
2004 | 13 | 10 | 23 |
2005 | 17 | 14 | 31 |
2006 | 17 | 16 | 33 |
2007 | 16 | 11 | 27 |
2008 | 13 | 10 | 23 |
2009 | 13 | 12 | 25 |
2010 | 18 | 9 | 27 |
2011 | 10 | 9 | 19 |
2012 | 12 | 9 | 21 |
2013 | 20 | 12 | 32 |
2014 | 15 | 9 | 24 |
2015 | 13 | 3 | 16 |
2016 | 9 | 3 | 12 |
2017 | 7 | 6 | 13 |
2018 | 11 | 4 | 15 |
2019 | 8 | 3 | 11 |
2020 | 3 | 4 | 7 |
2021 | 3 | 4 | 7 |
2022 | 0 | 2 | 2 |
2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antimetabolites, Antineoplastic" by people in Profiles.
-
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024 Feb; 99(2):E32-E36.
-
Significant erythroid megaloblastic changes in patients treated with allopurinol during maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 11; 70(11):e30631.
-
Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Clin Transl Sci. 2023 Nov; 16(11):2130-2143.
-
Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer. 2023 04 15; 129(8):1287-1294.
-
Azacitidine Monotherapy in Patients With Treatment-Na?ve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2023 02; 23(2):127-137.
-
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood. 2022 07 21; 140(3):285-289.
-
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021 11; 22(11):1597-1608.
-
Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2022 04; 22(4):236-250.
-
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. J Hematol Oncol. 2021 08 28; 14(1):133.
-
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)? Leuk Lymphoma. 2021 11; 62(11):2762-2767.